8-Year Data: BMS Opdivo & Yervoy Outperform in RCC Survival
Bristol Myers Squibb (BMS) announced that the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) continues to show significant long-term...
Jon Napitupulu
Opdivo & Cabometyx Show 4-Year Benefits in RCC Trial
Opdivo® (nivolumab) in combination with CABOMETYX® (cabozantinib) has shown continued benefits in the first-line treatment of advanced renal cell...
Arcus & Gilead: Quemliclustat Regimens Show Hope in Pancreatic Cancer
Arcus Biosciences, Inc. announced promising overall survival data from the ARC-8 Phase 1b trial, co-developed with Gilead Sciences. The...
Takeda’s HYQVIA Wins FDA Approval for CIDP Therapy
Takeda has announced that the FDA has approved HYQVIA® for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as...
FDA Nods Merck’s Keytruda for Stage III-IVA Cervical Cancer
Merck announced that the FDA has approved KEYTRUDA, their anti-PD-1 therapy, in combination with chemoradiotherapy (CRT) for treating patients...
Pfizer Tivdak SLA Accepted by FDA for Priority Cervical Cancer Review
Genmab A/S and Pfizer Inc. announced the FDA’s acceptance of the supplemental Biologics License Application (sBLA) to potentially convert...
ICON Sets Financial Forecast for 2024 Full Year
ICON plc, a global clinical research organization, has projected financial targets for the year ending December 31, 2024. The...
Innovative Merck-Inspirna Deal: New Hope in Cancer Battle
Merck KGaA, Darmstadt, Germany, has entered into a licensing agreement with Inspirna, Inc., New York, for the development of...
Revolutionary J-Brain Cargo® Tech in JCR Alexion Deal
JCR Pharmaceuticals Co., Ltd. has entered into a Research Collaboration, Option, and License Agreement with Alexion, AstraZeneca Rare Disease,...
China’s Bold Takeda Choice: LIVTENCITY’s Unique Edge
Takeda has announced the approval of LIVTENCITY® (maribavir) by the National Medical Products Administration (NMPA) of China for treating...